natgillin/translations-raw huggingface dataset:
An increased risk of bleeding is possible when Efient is co- administered with heparin.
Moguć je povećan rizik od krvarenja kada se Efient primjenjuje istodobno s heparinom.
An increased risk of bleeding may also be observed in patients who receive early administration of eptifibatide (e.g. upon diagnosis) compared to receiving it immediately prior to PCI, as seen in the Early ACS trial.
Povećani rizik od krvarenja se može vidjeti i u bolesnika koji rano prime eptifibatid (npr. odmah po postavljenoj dijagnozi), u odnosu na primjenu neposredno prije PCI, kao što je zamijećeno u ‘Early ACS’ ispitivanju.
An increased risk of bleeding may also be observed in patients who receive early administration of INTEGRILIN (e.g. upon diagnosis) compared to receiving it immediately prior to PCI, as seen in the Early ACS trial.
Povećani rizik od krvarenja se može vidjeti i u bolesnika koji rano prime INTEGRILIN (npr. odmah po postavljenoj dijagnozi), u odnosu na primjenu neposredno prije PCI, kao što je zamijećeno u ‘Early ACS’ ispitivanju.
an increased risk of bleeding, such as:
povećan rizik od krvarenja, poput:
An increased risk of bone fracture has been observed in patients taking this type of medicines.
Opažen je povećan rizik od prijeloma kostiju kod bolesnika koji uzimaju ovu vrstu lijekova.
An increased risk of bone fracture has beenobserved in patients taking this type of medicines.
Opažen je povećan rizik od prijeloma kostiju kod bolesnika koji uzimaju ovu vrstu lijekova.
An increased risk of bone freactures has been observed in patients taking this type of medicines.
Opažen je povećan rizik od prijeloma kostiju kod bolesnika koji uzimaju ovu vrstu lijekova.
An increased risk of cervical cancer in long-term users of COCs (> 5 years) has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).
U nekim je epidemiološkim ispitivanjima prijavljen povećan rizik od raka vrata maternice u dugotrajnih korisnica KOK-a (> 5 godina), no i dalje je sporno u kojoj se mjeri ovaj nalaz može pripisati istodobnim učincima spolnog ponašanja i drugih čimbenika poput humanog papiloma virusa (HPV).
An increased risk of DVT and PE is associated with the use of lenalidomide with dexamethasone in patients with multiple myeloma, and to a lesser extent in patients treated with melphalan and prednisone or as monotherapy in patients with myelodysplastic syndromes and mantle cell lymphoma treated with lenalidomide monotherapy (see section 4.5).
Povećan rizik od duboke venske tromboze i plućne embolije povezan je s primjenom lenalidomida s deksametazonom u bolesnika s multiplim mijelomom, a u manjoj mjeri u bolesnika liječenih melfalanom i prednizonom ili monoterapijom lenalidomidom u bolesnika s mijelodisplastičnim sindromima i limfomom plaštenih stanica (vidjeti dio 4.5).
An increased risk of grade 3-4 hypertension (including hypertension and one case of essential hypertension) has been observed in patients treated with the ZALTRAP/FOLFIRI regimen (see section 4.8).
U bolesnika liječenih protokolom ZALTRAP/FOLFIRI primijećen je povećan rizik od hipertenzije stupnja 3-4 (uključujući hipertenziju i jedan slučaj esencijalne hipertenzije) (vidjeti dio 4.8).
An increased risk of ICH has previously been observed in patients with advanced HIV disease/AIDS such as those treated in the Aptivus clinical trials.
Povećani rizik od ICH prethodno je primijećen u bolesnika s uznapredovalom HIV bolešću/AIDS-om, poput onih koji su bili uključeni u klinička ispitivanja s Aptivusom.
An increased risk of postural hypotension may occur in patients with severe renal insufficiency who are treated with potent CYP3A inhibitors or boosted protease inhibitors (PIs) and maraviroc.
U bolesnika s teškom bubrežnom insuficijencijom može doći do povećanog rizika posturalne hipotenzije ukoliko se liječe snažnim inhibitorima izoenzima CYP3A ili inhibitorima proteaze (IP) pojačanog djelovanja i maravirokom.
An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm3 (6.3 % versus 1.2 % for men with CD4 counts < 400 cells/mm3).
Povećan rizik primijećen je u muškaraca s detektabilnom HIV-1 RNK u plazmi i brojem CD4 >400 stanica/mm3 (6,3% naspram 1,2% za muškarce s brojem CD4 <400 stanica/mm3).
An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm3 (6.3 % versus 1.2 % for men with CD4 counts <400 cells/mm3).
Povećan rizik primijećen je u muškaraca s detektabilnom HIV-1 RNK u plazmi i brojem CD4 >400 stanica/mm3 (6,3% naspram 1,2% za muškarce s brojem CD4 <400 stanica/mm3).
An independent comparative trial (DRCR.net Protocol T) utilised a dosing regimen based on strict OCT and vision re-treatment criteria.
U neovisnom usporednom ispitivanju (DRCRnet Protocol T) koristio se režim doziranja koji se temeljio na strogim OCT i vizualnim kriterijima za ponovno liječenje.
An individual assessment whether increased frequency of surveillance is necessary should be performed based on the patient characteristics (e.g., age, underlying disease).
Kod svakog bolesnika treba na temelju bolesnikovih karakteristika (npr. dobi, bolesti u podlozi) procijeniti jesu li potrebne češće kontrole.
An individual patient data based meta-analysis, which included data from all 12 controlled clinical studies in anaemic cancer patients conducted with NeoRecormon (n=2301), showed an overall hazard ratio point estimate for survival of 1.13 in favour of controls (95 % CI 0.87, 1.46).
Meta-analiza podataka pojedinih bolesnika koja je uključivala podatke iz svih 12 kontroliranih kliničkih ispitivanja s lijekom NeoRecormon u anemičnih bolesnika oboljelih od raka (n=2301), pokazala je procjenu omjera ukupnog rizika za preživljenje od 1,13 u korist kontrolnih skupina (95 % CI 0,87; 1,46).
An infection called “thrush” which can affect the gut and is caused by a fungus.
gljivična infekcija zvana “kandidijaza” koja može zahvatiti crijeva
An infection characterised by high fever, sore throat, skin lesions and an extreme reduction of white blood cells (agranulocytosis).
infekcija praćena vrućicom, grloboljom, promjenama na koži i izrazitim smanjenjem broja bijelih krvnih stanica (agranulocitoza);
An infection could also give you a raised temperature (fever).
Od infekcije možete dobiti povišenu temperaturu (vrućicu).
An infection in your urine.
infekcija mokraćnih puteva
an infection of the blood caused by bacteria - this may be a sign of a low level of white blood cells
infekcija krvi prouzročena bakterijom - može biti znak malog broja bijelih krvnih stanica
An infection of the blood caused by bacteria.
infekcija krvi prouzročena bakterijama
An infection of the genitals caused by a fungus (thrush)
infekcija spolovila uzrokovana gljivicama (kandidijaza).
an infection of the lungs called “pneumonia” infections caused by bacteria that other antibiotics may not be able to kill
infekcije pluća koja se zove "pneumonija" infekcija uzrokovanih bakterijama koje drugi antibiotici možda ne mogu uništiti
An infection of the nose and throat, or sore throat.
infekcija nosa i grla ili grlobolja
An infection which affects your whole body (e.g., sepsis, seen as high temperature, increased heart rate or breathing)
infekcija koja utječe na cijelo tijelo (npr. sepsa, što se očituje kao visoka temperatura, ubrzani otkucaji srca ili ubrzano disanje)
An infection with Human Immunodeficiency Virus (HIV) without showing symptoms of HIV disease.
Infekciju virusom humane imunodeficijencije (HIV) ali bez vidljivih simptoma HIV-bolesti.
an infection,
infekciju,
An inflammation on the inside of the mouth.
upala usne šupljine
An inflammatory condition of the skin characterised by redness, itching, and oozing liquid- filled cysts which become scaly, crusted, or hardened (dermatitis acneiform)
Upalno stanje kože karakterizirano crvenilom, svrbežom, cistama punjenim tekućinom iz kojih curi iscjedak i koje postaju ljuskave, krastave ili stvrdnute (akneiformni dermatitis)
An infusion bag containing sodium chloride 9 mg/ml (0.9 %) solution for infusion is obtained suitable for intravenous administration.
Uzima se infuzijska vrećica koja sadrži 0,9% otopinu natrijeva klorida za infuziju koja je prikladna za intravensku primjenu.
An infusion bag may contain any of the following: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, sodium chloride 4.5 mg/mL and dextrose 25 mg/mL solution for injection (0.45% sodium chloride and 2.5% dextrose) or Lactated Ringer’s solution.
Infuzijska vrećica može sadržavati bilo koju od sljedećih otopina: otopinu natrijeva klorida 9 mg/ml (0,9%) za injekciju, otopinu glukoze 50 mg/ml (5%) za injekciju, otopinu natrijeva klorida 4,5 mg/ml i glukoze 25 mg/ml za injekciju (0,45% natrijevog klorida i 2,5% glukoze) ili otopinu Ringerova laktata.
An infusion reaction is any side effect, including an allergic reaction, occurring during the infusion or within a day following infusion (see section 4 “Possible side effects”).
Bilo koja reakcija na infuziju je nuspojava, uključujući alergijsku reakciju, koja se događa za vrijeme infuzije ili do kraja idućeg dana nakon nje (pogledajte dio 4 „Moguće nuspojave”).
An infusion reaction was defined in the pivotal trial CLEOPATRA in metastatic breast cancer as any event reported as hypersensitivity, anaphylactic reaction, acute infusion reaction or cytokine release syndrome occurring during an infusion or on the same day as the infusion.
U pivotalnom ispitivanju CLEOPATRA u metastatskom raku dojke, reakcija na infuziju je definirana kao bilo koji događaj prijavljen kao preosjetljivost, anafilaktička reakcija, akutna reakcija na infuziju ili sindrom otpuštanja citokina, koji se javio tijekom infuzije ili na dan primjene infuzije.
An infusion set equipped with an in-line 0.2 µm filter can be used.
Može se koristiti komplet za infuziju opremljen ugrađenim filterom od 0,2 µm.
An infusion set equipped with an in-line 0.2µm filter can be used.
Može se upotrijebiti komplet za infuziju opremljen ugrađenim filtrom od 0,2 µm.
An infusion- associated reaction can sometimes be very severe.
Reakcija povezana s infuzijom katkad može biti vrlo teška.
An initial dose of 6 mg contains up to 150 mg of alcohol which isequivalent to 3 mL beer or 1.25 mL wine.
Početna doza od 6 mg sadrži do 150 mg alkohola, što odgovara 3 ml piva ili 1,25 ml vina.
An initial dose of 80 IU/kg VWF:RCo may be required, especially in patients with type
Može biti potrebna početna doza od 80 IU/kg VWF:RCo, posebice u bolesnika s tipom
An initial dose of 80 IU/kg VWF:RCo may be required, especially in patients with type 3 VWD where maintenance of adequate levels may require greater doses than in other types of VWD.
Može biti potrebna početna doza od 80 IU/kg VWF:RCo posebice u bolesnika s tipom 3 von Willebrandove bolesti, gdje održavanje odgovarajućih razina može zahtijevati veće doze od onih u drugim tipovima te bolesti.
An initial dose reduction of
Preporučuje se smanjenje
An initial oral dose of 0.30 mg/kg/day should be administered in 2 divided doses (e.g. morning and evening).
Početnu peroralnu dozu od 0,30 mg/kg na dan treba primijeniti u 2 odvojene doze (npr. ujutro i navečer).
An initial peak in plasma concentrations of granisetron, attributable to the intravenous dose, was reached at 10 minutes post-administration.
Deset minuta nakon primjene dostignute su početne vršne koncentracije granisetrona u plazmi, što se može pripisati intravenskoj dozi.
An Initiation Pack is available containing the first 2 doses (63 micrograms and 94 micrograms).
Dostupno je početno pakiranje koje sadrži prve dvije doze (63 mikrograma i 94 mikrograma).
An instruction how to take Pradaxa
Upute kako uzimati Pradaxu
An instructional video on how to prepare and administer ALPROLIX is available by scanning the QR code with a smartphone or via the website
Skeniranjem QR koda pomoću pametnog telefona ili putem internetske stranice možete pristupiti videu s uputama o tome kako pripremiti i primijeniti lijek ALPROLIX
An interaction study with gemfibrozil, an in vitro inhibitor of OAT3 and OATP1B1/1B3 transporters, showed that empagliflozin Cmax increased by 15% and AUC increased by 59% following co- administration.
Ispitivanje interakcija s gemfibrozilom, in vitro inhibitorom prijenosnika OAT3 i OATP1B1/1B3, pokazala je da je Cmax empagliflozina povećan za 15%, a AUC za 59% nakon istodobne primjene.
An interaction with trimethoprim, a constituent of co-trimoxazole, causes a 40 % increase in lamivudine exposure at therapeutic doses.
Interakcija s trimetoprimom, sastojkom kotrimoksazola, uzrokuje 40% porast izloženosti lamivudinu u terapijskim dozama.
An interim analysis of RE-VERSE AD included data for 123 patients: 66 patients with serious bleeding (Group A) and 57 requiring an urgent procedure (Group B).
Interim analiza ispitivanja RE-VERSE AD uključivala je podatke za 123 bolesnika: 66 bolesnika s ozbiljnim krvarenjem (skupina A) i 57 bolesnika kojima je bio potreban hitan postupak (skupina B).
An interim analysis was conducted on 61 subjects who received sofosbuvir and ribavirin; the majority of subjects had HCV genotype 1, 44 subjects were CPT class A and 17 subjects were CPT class B. Of these 61 subjects, 44 subjects underwent liver transplantation following up to 48 weeks of treatment with sofosbuvir and ribavirin; 41 had HCV RNA <LLOQ at the time of transplantation.
Privremena analiza bila je provedena na 61 ispitaniku koji je primao sofosbuvir i ribavirin; većina ispitanika imala je HCV-genotip 1, 44 ispitanika imalo CPT stadij A, a 17 ispitanika imalo je CPT stadij B. Od 61 ispitanika, u 44 ispitanika transplantacija jetre obavljena je nakon najviše 48 tjedana liječenja sofosbuvirom i ribavirinom; 41 je imao HCV RNK < donje granice kvantifikacije u vrijeme transplantacije (LLOQ).
An interim analysis was performed when all subjects had completed the month 48 study visit.
Interim analiza napravljena je kada su sve ispitanice završile posjetu u 48 mjesecu ispitivanja.
An international, multicenter, randomized, open-label, comparative Phase 3 efficacy and safety study was conducted in newly diagnosed Ph+ CP CML patients.
Provedeno je međunarodno, multicentrično, randomizirano, otvoreno, usporedno ispitivanje, faza 3, za utvrđivanje djelotvornosti i sigurnosti u novodijagnosticiranim bolesnicima s Ph+ CP KML-om.
An interruption of dosing should be considered if intense local inflammatory reactions occur (see section 4.4) or if infection is observed at the treatment site.
Liječenje je potrebno prekinuti ako dođe do izražene lokalne upalne reakcije na koži (vidjeti dio 4.4) ili infekcije na području liječenja.
An introduction in each guide will inform the reader that the purpose of the guide is to tell them that a foetal exposure must be avoided and how to minimize the risk of birth defects and miscarriage associated with mycophenolate mofetil.
Uvod svakog vodiča čitatelju će pojasniti da je svrha vodiča upozoriti ga da mora izbjegavati izlaganje fetusa lijeku i objasniti mu kako minimizirati rizik od prirođenih mana i spontanog pobačaja koji je povezan s primjenom mofetilmikofenolata.
An irritation of the eyes (conjunctivitis).
nadraženost očiju (konjunktivitis).
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces.
U urinu, plazmi i fecesu pronađen je jedan N- desmetil metabolit koji je pokazao sličnu ili manju aktivnost od ishodišnog spoja u testu koji koristi stanice (engl. cell-based assay).
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces.
U urinu, plazmi i fecesu pronađen je jedan N- desmetil metabolit koji je pokazao sličnu ili manju aktivnost od ishodišnog spoja u testu koji koristi stanice (engl.cell-based assay).
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces.
U urinu, plazmi i fecesu pronađen je jedan N- desmetil metabolit koji je pokazao sličnu ili manju aktivnost od roditeljskog spoja u staničnoj kulturi.
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces.
U urinu, plazmi i fecesu pronađen je jedan N- desmetil metabolit koji je pokazao sličnu ili manju aktivnost od roditeljskog spoja u testu koji koristi stanice (engl. cell-based assay).
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces.
U urinu, plazmi i fecesu pronađen je jedan N-desmetil metabolit koji je pokazao sličnu ili manju aktivnost od ishodišnog spoja u testu koji koristi stanice (engl. cell- based assay).
An objective response was observed for four of six evaluable adolescent in an interim analysis of Study 5.
Zabilježen je objektivni odgovor u 4 od 6 procjenjivih adolescenata u interim analizi Ispitivanja 5.
An observation period of 30 to 60 minutes is recommended after each Perjeta infusion and before commencement of any subsequent infusion of trastuzumab or docetaxel (see section 4.4).
Preporučuje se razdoblje promatranja u trajanju od 30 do 60 minuta nakon svake infuzije lijeka Perjeta i prije početka svake infuzije trastuzumaba ili docetaksela koja slijedi iza nje (vidjeti dio 4.4).
An observational non-interventional Registry in patients with PNH (M07-001) was also initiated to characterize the natural history of PNH in untreated patients and the clinical outcomes during Soliris treatment.
Bio je pokrenut i opservacijski neintervencijski Registar bolesnika s PNH-om (M07-001) kako bi se opisao prirodni tijek PNH-a kod neliječenih bolesnika i klinički ishodi tijekom liječenja lijekom Soliris.
An observational retrospective cohort study of ospemifene to assess the incidence of venous thromboembolism and other safety concerns as agreed in the risk management plan, in VVA patients treated with ospemifene compared to 1) patients newly prescribed SERMs for oestrogen-deficiency conditions or breast cancer prevention, and 2) the incidence in untreated VVA patients.
Opservacijsko retrospektivno ispitivanje kohorti koje primaju ospemifen radi ocjene incidencije venske tromboembolije i drugih sigurnosnih pitanja kako je to dogovoreno planom upravljanja rizikom, u bolesnica s VVA liječenih ospemifenom u usporedbi s 1) bolesnicama kojima su nedavno propisani selektivni modulatori estrogenskih receptora zbog stanja deficita estrogena ili radi prevencije raka dojke, i 2) incidencijom u neliječenih bolesnica s VVA.
An occasional use of acetylsalicylic acid (no more than 1000 mg in any 24 hour period), a substance present in many medicines used to relieve pain and lower fever, should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Povremeno uzimanje acetilsalicilatne kiseline (ne više od 1000 mg u 24 sata), tvari prisutne u mnogim lijekovima za ublažavanje boli i snižavanje temperature, općenito ne izaziva probleme, ali o produljenom uzimanju u drugim okolnostima morate razgovarati s liječnikom.
An occasional use of acetylsalicylic acid (not more than 1000 mg in 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Povremeno uzimanje acetilsalicilatne kiseline (ne više od 1000 mg u 24 sata) općenito ne izaziva probleme, ali o produljenom uzimanju u drugim okolnostima morate razgovarati s liječnikom.
An occasional use of acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever (no more than 1,000 mg in any 24 hour period), should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Povremeno uzimanje acetilsalicilatne kiseline, tvari prisutne u mnogim lijekovima za ublažavanje boli i snižavanje temperature (ne više od 1000 mg u 24 sata) općenito ne izaziva probleme, ali o produljenom uzimanju u drugim okolnostima morate razgovarati s liječnikom.
An odds ratio (OR) > 1 indicates an advantage for BzmbR-CAP.
OR > 1 ukazuje na prednost za uvodno liječenje za BzmbR-CAP.
An odds ratio (OR) > 1 indicates an advantage for BzR-CAP.
Omjera izgleda (OR) > 1 ukazuje na prednost za BzR-CAP.
An on-line video to further elaborate on the required calculation and administration of the drug
On-line video s dodatnom razradom potrebnog izračuna i primjene lijeka
An ongoing randomised, double-blinded study (MERIT), is exploring Maraviroc versus efavirenz, both in combination with zidovudine/lamivudine (n=721, 1:1).
Randomizirano, dvostruko slijepo ispitivanje (MERIT) koje je još u tijeku, ispituje maravirok u usporedbi s efavirenzom, oboje u kombinaciji sa zidovudinom/lamivudinom (n=721, 1:1).
An open label non randomised Phase I/II study was conducted to determine the safety and efficacy of bortezomib in patients with previously treated light-chain (AL) Amyloidosis.
Provedeno je ispitivanje otvorenog, nerandomiziranog tipa faze I/II da bi se utvrdila sigurnost i djelotvornost primjene bortezomiba u bolesnika prethodno liječenih zbog amiloidoze lakih lanaca (AL).
An open label non randomised Phase I/II study was conducted to determine the safety and efficacy of bortezomib in patients with previously treated light-chain (AL) Amyloidosis.
Provedeno je ispitivanje otvorenog, nerandomiziranog tipa faze I/II da bi se utvrdila sigurnost i djelotvornost primjene bortezomibau bolesnika prethodno liječenih zbog amiloidoze lakih lanaca (AL).
An open label non randomised Phase I/II study was conducted to determine the safety and efficacy of VELCADE in patients with previously treated light-chain (AL) Amyloidosis.
Provedeno je ispitivanje otvorenog, nerandomiziranog tipa faze I/II da bi se utvrdila sigurnost i djelotvornost primjene VELCADEa u bolesnika prethodno liječenih zbog amiloidoze lakih lanaca (AL).
An open label trial based on a CHMP approved protocol, comparing RET negative and RET positive patients with sporadic medullary thyroid cancer treated with vandetanib.
Otvoreno ispitivanje prema protokolu odobrenom od strane CHMP-a, u kojemu će se usporediti bolesnici sa sporadičnim medularnim karcinomom štitnjače liječeni vandetanibom koji imaju negativan status mutacije protoonkogena RET s onima koji imaju pozitivan status RET mutacije.
An open label, randomised, Phase III non-inferiority study compared the efficacy and safety of the subcutaneous administration of VELCADE versus the intravenous administration.
U otvorenom, randomiziranom ispitivanju neinferiornosti, faze III uspoređena je djelotvornost i sigurnost supkutane primjene VELCADEa, u odnosu na intravensku primjenu.
An open label, repeat dose study (3 cycles of 6 weeks of treatment, followed by 4 weeks off treatment) showed that episodic use with multiple courses of eltrombopag has demonstrated no loss of response.
Otvoreno ispitivanje s ponavljanim dozama (3 ciklusa po 6 tjedana liječenja, nakon kojih su uslijedila 4 tjedna bez liječenja) pokazalo je da periodična primjena eltrombopaga u višekratnim ciklusima ne pokazuje gubitak odgovora.
an open sore or hole in the lining of the stomach or small intestine (the signs may include abdominal pain, feeling bloated, black tarry stools or blood in your stools (faeces) or blood in your vomit),
otvorena rana ili napuknuće u stijenci želuca ili tankog crijeva (znakovi mogu biti bol u trbuhu, osjećaj napuhnutosti, crna katranasta stolica ili krv u stolici te krv kod povraćanja),
An open-label extension of this study showed no further reductions in free and total testosterone concentrations over a period of 3 years in cinacalcet-treated patients.
Otvorena, produljena trogodišnja studija nije pokazala daljnje sniženje koncentracije slobodnog i ukupnog testosterona u bolesnika liječenih sinakalcetom.